Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose

Procter & Gamble (P&G)

Status

Completed

Conditions

Impaired Fasting Glucose

Treatments

Dietary Supplement: Microcrystalline Cellulose

Dietary Supplement: psyllium

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01549600

2011063

Details and patient eligibility

About

The Purpose of this study is to compare the effects of 2 types of dietary fiber, psyllium and microcrystalline cellulose (MCC), on glycemic measures in subjects with impaired fasting glucose.

Full description

This study will be conducted at a single study center. Approximately 40 subjects with pre-type 2 diabetes will be enrolled and randomized in this study.

This 22-week study consists of 3 periods: an 8-week treatment period (Visits 2-4), a 6-week washout period, and an 8-week treatment period (Visits 5-7).

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

be male or female,
at least 18 years of age
in generally good health for the pre-type 2 diabetes population;
if female, be postmenopausal or if of child-bearing capacity agree to use an adequate form of contraception
have not used any psyllium containing products within the past 3 months;
be willing to refrain from taking any psyllium containing products during the study;
be willing to maintain a lifestyle habits for the duration of the study;
have a fasting serum glucose of 110 - 125 mg/dL

Exclusion criteria

if female, are pregnant or nursing (lactating);
have a history of diabetes (diagnosis) or is currently taking medications for diabetes
participated in a clinical drug study or used investigational drug during the previous 30 days;
have symptoms and signs suggestive of significant underlying disease, or acute onset of new symptoms and signs of major organ disease, that could become unstable during the trial requiring urgent medical intervention
have evidence of or treatment history of malignancy within the previous 5 years;
currently alcohol dependent;
used anti-psychotics in the previous 3 months;
used systemic steroidal agents within the last 30 days;
had used oral or systemic antibiotics or any over-the-counter (OTC) bactericidal medication (eg, bismuth salts) within the last 30 days;
has been taking any medication that may affect blood glucose or GI motility (eg, calcium channel blockers, beta blockers, antimuscarinics, salicylates etc.) for less than 30 days or 5 times the half life of the drug (need to be stable on the medication);
have evidence of immunodeficiency including subjects currently taking systemic corticosteroids or immunosuppressive drugs
have a major psychiatric disorder, including major depression, psychoses, alcohol or substance abuse within the past 2 years;
has a known sensitivity or allergy to any components of study products, including psyllium and aspartame (see Section 3.5.3);
were previously screened (ie, Visit 1 procedures) for participation in this study and failed to meet entry criteria;
have difficulty swallowing